Your browser doesn't support javascript.
loading
Evolocumab's Long-Term Mortality Risk Unclear Due to Shortened Follow-Up of FOURIER.
van Bruggen, Folkert H; Luijendijk, Hendrika J.
Affiliation
  • van Bruggen FH; Department of General Practice and Elderly Care Medicine, University Medical Center Groningen, University of Groningen, Postbus 196, 9700 AD, Groningen, The Netherlands.
  • Luijendijk HJ; Department of General Practice and Elderly Care Medicine, University Medical Center Groningen, University of Groningen, Postbus 196, 9700 AD, Groningen, The Netherlands. h.j.luijendijk@umcg.nl.
Am J Cardiovasc Drugs ; 22(1): 5-8, 2022 Jan.
Article in En | MEDLINE | ID: mdl-34008143
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Antibodies, Monoclonal, Humanized / PCSK9 Inhibitors Type of study: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Am J Cardiovasc Drugs Journal subject: ANGIOLOGIA / CARDIOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2022 Document type: Article Affiliation country: Netherlands Country of publication: New Zealand
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Antibodies, Monoclonal, Humanized / PCSK9 Inhibitors Type of study: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Am J Cardiovasc Drugs Journal subject: ANGIOLOGIA / CARDIOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2022 Document type: Article Affiliation country: Netherlands Country of publication: New Zealand